SCHEMBL84268

SCHEMBL84268

CC(O)c1c(N)cccc1C#N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
TSHR P16473 3/20 0.38
MAPK1 P28482 2/20 0.38
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
ADRB3 P13945 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.35
MAP2K1 Q02750 1/20 0.34
PIK3CA P42336 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NOTUM Q6P988 1/20 0.31
LMNA P02545 2/20 0.31
HPGD P15428 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27784531 0.85 CYP3A4 (0.43) CYP3A4CYP1A2CYP2C9CYP2C19TSHR
SCHEMBL6089702 0.81 TSHR (0.38) CYP3A4CYP1A2CYP2C9CYP2C19TSHR
SCHEMBL4852014 0.80 CYP3A4 (0.43) CYP3A4CYP1A2TSHRMAPK1ADRB1
SCHEMBL807524 0.78 TSHR (0.46) TSHRMAPK1L3MBTL1MAP2K1SMN1; SMN2
SCHEMBL84270 0.74 TSHR (0.36) CYP3A4CYP1A2CYP2C9CYP2C19TSHR
SCHEMBL1464678 0.74 CYP3A4 (0.39) CYP3A4CYP1A2TSHRPIK3CASMN1; SMN2
SCHEMBL3462087 0.74 TSHR (0.36) TSHRMAPK1L3MBTL1SMN1; SMN2NOTUM
SCHEMBL8973695 0.72 CD44 (0.48) CYP3A4CYP1A2CYP2C9TSHRPIK3CA
SCHEMBL5801533 0.71 CYP1A2 (0.36) CYP3A4CYP1A2CYP2C9CYP2C19TSHR
SCHEMBL5111434 0.71 ALDH1A1 (0.48) CYP3A4CYP1A2TSHRADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122892-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-05-17 US disclosed
US-8129403-B2 e.g. 2-[9-(5-Cyclopropyl-1H-pyrazol-3-yl)-6-methyl-9H-purin-2-ylamino]-2-(4-fluorophenyl)ethanol; tropomyosin-related kinases (Trk's) inhibitor; anticarcinoganic agent; solid tumors and leukemia ASTRAZENECA AB (SE) 2012-03-06 US disclosed
US-20090227648-A1 PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER ASTRAZENECA AB 2009-09-10 US disclosed
US-20080176872-A1 Chemical Compounds ASTRAZENECA AB (SE) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176872-A1 Chemical Compounds TP53, XPOT, KRAS CYP3A4 68/4885CYP1A2 69/4885CYP2C9 193/4885
US-20120122892-A1 CHEMICAL COMPOUNDS TP53, XPOT, KRAS CYP3A4 62/4885CYP1A2 59/4885CYP2C9 174/4885
US-20090227648-A1 PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER TP53, PDK2, PDK1 CYP3A4 61/4885CYP1A2 256/4885CYP2C9 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.